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Immunophenotypic analysis
• The iMSC population had greater than 95% expression of the positive 
cell surface markers CD105+ and CD73+ and ~79% expression for the 
positive cell surface marker CD90+.  Expression of negative cell surfaces 
markers was less than 1% (Figure 3).
Multilineage differentiation
• Successful multilineage differentiation of the iMSCs was observed 
(Figure 4).  Positive staining with Alcian Blue, Alizarin Red S and 
BODIBY indicate chondrogenesis, osteogenesis and adipogenesis 




Figure 4. Representative images of the differentiated induced mesenchymal stem cells. (A)
Chondrogenesis staining after 21 days by Alcian Blue. (B) Osteogenesis staining after 14 days by Alizarin Red
S. (C) Adipogenesis immunostaining after 14 days with BODIPY and DAPI.
Figure 1
Figure 1. Characterization of human iPSC line (MC0192). (A) In vitro differentiation of the control iPSC line into all
three primary germ layers. Cells were immunostained for SOX17 (endoderm), Brachyury (mesoderm), Nestin (ectoderm),
and DAPI following fixation. Scale bar: 100 μm. Magnification: 20X. (B) Immunostaining of pluripotency markers (TRA-1-
60 and Nanog), and DAPI (blue) Scale bar: 100μm. Magnification: 20X. (C) qRT-PCR measurements of mRNA levels of
the reprogramming factors in a commercial iPSC and a control iPSC line (MC0192), which was quantified in relation to
the skin fibroblast line.
Methods
iPSC line
The iPSC line derived from skin fibroblasts of a healthy individual (MC0192) was 
used in this study. The pluripotency was validated by three germ layer 
differentiation(endoderm, mesoderm and ectoderm) and pluripotency assay through 
immunostaining. The mRNA expressions of stem cell markers were also confirmed 
by RT-qPCR (Figure 1).
Conversion of iPSCs to iMSCs
The iPSCs were differentiated to MSCs through published protocols with minor 
modification. Embryonic bodies (EBs) were formed from iPSCs by culturing in a 
round bottom dish. The EBs were further differentiated into MSCs on a gelatin-
coated dish in a TGF-β containing medium (Figure 2).
Immunophenotypic analysis for iMSCs
The iMSCs were verified by flow cytometry for cell surface marker expression with 
BM-MSC used as a positive control.  Briefly, cells were expanded to passage 3 
then stained with antibodies for the MSC positive cell surface markers CD105, 
CD90 and CD73. Expression of the cell surface markers was verified using an 
Attune NxT flow cytometer.
Multilineage differentiation of iMSCs
The iMSCs were differentiated into chondrocytes, adipocytes and osteocytes using 
commercially available medium.  For osteogenesis and adipogenesis, cells were 
grown for 12-14 days in specific differentiation medium and then fixed in 4% 
paraformaldehyde.  Adipocyte differentiation was confirmed using BODIPY 
493/503, a fluorescent stain that indicates the presence of lipids.  Osteocytes were 
confirmed using Alizarin Red S, a stain that detects extracellular calcium deposits.  
For chondrocyte differentiation, cells were grown for 21 days under specific 
differentiation medium and then fixed with 4% paraformaldehyde. Cells were then 
stained with Alcian Blue, a stain that detects cartilage extracellular matrix. 
Abstract Figure 2
Figure 2. Visualization of the experimental design. The iPSCs from human fibroblasts were converted to 
mesenchymal stem cells (MSCs) through the use of induction media and supplements over ~2 weeks.  To 
confirm the conversion, induced MSC should display plastic adherence,  have positive expression of specific 
cell surface markers and be capable of differentiating into chondrocytes, adipocytes and osteocytes.  
Figure 3 
Figure 3. Flow cytometry data for induced mesenchymal stem cells. iMSCs at passage 3 were stained with
antibodies specific to cell surfaces markers CD105+, CD90+ and CD73+ and a cocktail of negative control
markers. The iMSC population was over 95% for the cell surface markers CD105+ and CD73+ and ~79% for
CD90+ when analyzed by FACS.
Discussion & Future Directions
In this study, we have established a method to generate mesenchymal 
stem cells (MSCs) from induced pluripotent stem cells (iPSCs).  We have 
demonstrated that our induced MSCs (iMSCs) meet the criteria set by the 
International Society of Cellular Therapy (ISCT).  First, plastic adherence 
was evident during the culturing of the iMSCs Second, the majority of the 
iMSC population expressed the positive cell surface markers CD105+, 
CD90+ and CD73+ while showing less than 1% of the negative cell surface 
markers providing evidence that the iPSC cells have been differentiated 
into MSC.  Last, multilineage differentiation of the iMSCs was confirmed 
through fluorescent and immunohistological assays after 14-21 days in 
appropriate culture medium.  Experiments are currently planned to test the 
effectiveness of the iMSCs in T-cell proliferation. We also plan to conduct 
animal models to investigate the therapeutic effects of iMSCs on sepsis 
and radiation induced brain injury.
Our ultimate goal is to 
generate iMSCs from 
GMP-grade iPSCs, and 
develop new regenerative 




hepatic diseases, lung 
injury, renal failure, 
cancers, wound healing 
and infections. 
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Adult stem cells represent self-renewing, multipotent cells that are capable of 
producing mature cells of another tissue through differentiation. Stem cells can 
be sourced from a variety of tissues such as bone marrow, adipose tissue, and 
cord blood. Bone-marrow derived mesenchymal stem cells (BM-MSC) have the 
ability to differentiate, lack of ethical concerns, no teratoma potential, easily 
cultured and expanded ex vivo, and are immunomodulatory via paracrine 
effects. Thus, BM-MSCs have been actively used as a therapeutic agent in a 
variety of clinical trials to treat diverse diseases including neurological diseases, 
cardiovascular diseases, hepatic diseases, lung injury, renal failure, cancers, 
wound healing and infections. However, concerns have been raised related to 
high cell population heterogeneity, poorly understood homing capabilities, and a 
tendency to lose biological functions in vitro with each passage. Recently, 
induced pluripotent stem cells (iPSCs) have emerged as a new class of stem 
cells with greater versatility. iPSC technology allows for potential treatment of 
any degenerative diseases or injury due to the pluripotent potentials and 
unlimited manufacturing. In this study, we established a method to generate 
iPSC-derived MSCs (iMSCs). The International Society for Cellular Therapy 
(ISCT) have imposed several criteria for MSCs, which include 1) plastic 
adherence, 2) stable expression of CD90, CD105, and CD73 cell surface 
markers, and 3) ability to differentiate into adipocytes, chondrocytes, and 
osteoblasts. Our results demonstrated that iMSCs have similar property to that 
of BM-MSCs by satisfying the criteria. Future directions include creating clinical 
grade iMSCs which can be used for future regenerative therapies. 
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